Korean J Urol.  2008 Dec;49(12):1149-1154.

The Clinical Features of Complicated Urinary Tract Infections by Pseudomonas aeruginosa

• Lee JW
• Oh KJ
• Park SC
• Rim JS

Abstract

PURPOSE: Pseudomonas aeruginosa is an important pathogen in complicated urinary tract infections(UTIs). The aim of this study was to evaluate the isolation rate of Pseudomonas from patients with UTIs and to define the accompanying clinical features.
MATERIALS AND METHODS
Between January 2000 and December 2006, we retrospectively reviewed the medical records of 170 urology patients with Pseudomonas UTIs. We analyzed the isolation rate of Pseudomonas in patients with UTIs and determined the antibiotic susceptibilities. We also analyzed the clinical features and underlying diseases in patients with Pseudomonas UTIs.
RESULTS
Pseudomonas was cultured in the urine from 234 of 3,470 patients (6.6%) with positive urine cultures. One hundred seventy of 234 patients had underlying urologic disease. Eighty-two patients(48.2%) had indwelling urinary catheters and 34 patients(20.0%) had diabetes. Patients with catheters tended to have febrile UTIs compared to patients without catheters(70.7% vs. 42.0%, respectively). The isolation rate of Pseudomonas increased between 2000 and 2006(2.8% vs. 13.1%, respectively). The sensitivity of Pseudomonas to most antibiotics decreased between 2000 and 2006. Patients with neurogenic disease and catheters were more easily infected with Pseudomonas.
CONCLUSIONS
The isolation rate of Pseudomonas in urine cultures is on the rise. Patients with UTIs and catheters, unlike those without, have high fevers. Because the sensitivity of Pseudomonas to antimicrobial agents has decreased, we need to choose appropriate antibiotics through urine cultures and antibiotics sensitivity tests in treating complicated UTIs.

Keyword

Urinary tract infections; Pseudomonas aeruginosa; Anti-bacterial agents

MeSH Terms

Anti-Bacterial Agents
Anti-Infective Agents
Catheters
Fever
Humans
Medical Records
Pseudomonas
Pseudomonas aeruginosa
Retrospective Studies
Urinary Catheters
Urinary Tract
Urinary Tract Infections
Urologic Diseases
Urology
Anti-Bacterial Agents
Anti-Infective Agents

Figure

• 

  Fig. 1 The isolation rates of Pseudomonas aeruginosa based on year of collection.

• 

  Fig. 2 The antimicrobial sensitivities of Pseudomonas aeruginosa based on year of isolation.

Reference

1. Mulholland SG, Jacobs JA. Management of urinary tract infections. AUA Update Series. 1982. 1:1–8.

2. Ryu KH, Kim MK, Jeong YB. A recent study on the antimicrobial sensitivity of the organisms that cause urinary tract infection. Korean J Urol. 2007. 48:638–645.

3. Pollack M. Mandell GL, Bennett JE, Dolin RM, editors. Pseudomonas aeruginosa. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 2000. 5th ed. Philadelphia: Churchill Livingstone;2310–2335.

4. Spencer RC. An 8 year microbe base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom. J Antimicrob Chemother. 1996. 37:295–301.

5. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data, summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004. 32:470–485.

6. Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis. 2002. 43:239–243.

7. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. NCCLS document M7-A5. 2000. Wayne: NCCLS.

8. Naber KG, Bishop MC, Bjerklund-Johansen TE, Botto H, Cek M, Grabe M, et al. . The management of urinary and genital tract infections. European Association of Urology Guidelines. 2006. Arnhem: Drukkerij Gelderland;1–126.

9. Lee JK, Sohn ES, Yoo YS, Yoo JI, Lee EH, Lee KR, et al. Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from non-tertiary care hospitals in Korea, 2002-2004. Infect Chemother. 2006. 38:1–10.

10. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary infections in women: a nationwide analysis. Clin Infect Dis. 2001. 33:89–94.

11. Mathai D, Jones RN, Pfaller MA. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis. 2001. 40:129–136.

12. Song HJ, Kim SJ. A study of antimicrobial sensitivity to the causative organism of urinary tract infection. Korean J Urol. 2005. 46:68–73.

13. Cordero L, Sananes M, Coley B, Hogan M, Gelman M, Ayers LW. Ventilator-associated pneumonia in very low-birth-weight infants at the time of nosocomial bloodstream infection and during airway colonization with Pseudomonas aeruginosa. Am J Infect Control. 2000. 28:333–339.

14. Ono Y. Pseudomonas aeruginosa. Nippon Rinsho. 2002. 60:2150–2155.

15. Shigemura K, Arakawa S, Sakai Y, Kinoshita S, Tanaka K, Fujisawa M. Complicated urinary tract infection caused by Pseudomonas aeruginosa in a single institution (1999-2003). Int J Urol. 2006. 13:538–542.

16. Kumon H, Ono N, Iida M, Nickel JC. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother. 1995. 39:1038–1044.